Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Challenges to the development of antigen-specific breast cancer vaccines
Autore:
Scanlan, MJ; Jager, D;
Indirizzi:
Mem Sloan Kettering Canc Ctr, New York Branch Human Canc Immunol, Ludwig Inst Canc Res, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr New YorkNY USA 10021 New York, NY 10021 USA Med Klin 2, Frankfurt, Germany Med Klin 2 Frankfurt GermanyMed Klin 2, Frankfurt, Germany
Titolo Testata:
BREAST CANCER RESEARCH
fascicolo: 2, volume: 3, anno: 2001,
pagine: 95 - 98
SICI:
1465-542X(2001)3:2<95:CTTDOA>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
DENDRITIC CELLS; T-CELL; CARCINOEMBRYONIC ANTIGEN; ANTITUMOR IMMUNITY; PROSTATE-CANCER; HUMAN-MELANOMA; IN-VIVO; ANTIBODY; LYMPHOCYTES; RESPONSES;
Keywords:
cancer vaccines; dendritic cells; immunotherapy; tumor antigens;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Scanlan, MJ Mem Sloan Kettering Canc Ctr, New York Branch Human Canc Immunol, Ludwig Inst Canc Res, 1275 York Ave, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY USA 10021
Citazione:
M.J. Scanlan e D. Jager, "Challenges to the development of antigen-specific breast cancer vaccines", BREAST CA R, 3(2), 2001, pp. 95-98

Abstract

Continued progress in the development of antigen-specific breast cancer vaccines depends on the identification of appropriate target antigens, the establishment of effective immunization strategies, and the ability to circumvent immune escape mechanisms. Methods such as T cell epitope cloning and serological expression cloning (SEREX) have led to the identification of a number target antigens expressed in breast cancer. Improved immunization strategies, such as using dendritic cells to present tumor-associated antigensto T lymphocytes, have been shown to induce antigen-specific T cell responses in vivo and, in some cases, objective clinical responses. An outcome ofsuccessful tumor immunity is the evolution of antigen-loss tumor variants. The development of a polyvalent breast cancer vaccine, directed against a panel of tumor-associated antigens, may counteract this form of immune escape.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/04/20 alle ore 23:58:41